Intezyne creates partnership

Intezyne, a young pharmaceutical company operating out of the University of South Florida's Research Park, has struck a deal with an unnamed pharmaceutical company to accelerate bringing its cancer-treating product to market.

Kevin Sill, chief science officer and subject of a Jan. 15, 2010 Review story (link), says the deal will help the company reach clinical trials, and puts Intezyne “in a position to raise capital” for the future.

The search for that capital will take the company to Washington, D.C., and Las Vegas later this month. Sill says Intezyne still needs to find a significant amount of money — between $10 and $20 million — to complete further testing for its product.